Thesis
ELI-002 7P's Phase 3 in R0-resected PDAC hinges on whether a post-hoc subgroup signal survives prospective testing and whether financing materializes
ELI-002 7P is an mKRAS-targeting amphiphile vaccine that failed its pre-specified ITT primary endpoint in Phase 2 AMPLIFY-7P for adjuvant PDAC, with any forward case resting entirely on a post-hoc HR of 0.65 in R0-resected patients. The thesis now depends on whether FDA accepts the post-hoc subgroup as a valid Phase 3 registrational basis and whether Elicio secures financing before Q4 2026 runway expiration. The company faces the dual threat of regulatory skepticism toward post-hoc endpoint selection and the absence of any approved adjuvant immunotherapy comparator to anchor a Phase 3 design, while KRAS-targeted agents like Mirati's adagrasib and Amgen's sotorasib advance in PDAC.
Focus
ELI-002 7P Phase 3 initiation in adjuvant PDAC (R0 resected)
H2 2026
Bull
Elicio secures sufficient financing and reaches favorable End-of-Phase 2 alignment with FDA on a Phase 3 design anchored in the R0-resected population with extended dosing and DFS as the primary endpoint; trial initiation would validate the post-hoc signal as a credible regulatory hypothesis, re-rate the stock, and attract partnership interest given the strong T-cell response correlation data (HR 0.22 for mKRAS-specific responders).
Bear
The company fails to raise adequate capital before its Q4 2026 cash runway expires, preventing Phase 3 initiation entirely; alternatively, FDA declines to accept the R0 post-hoc subgroup as sufficient basis for a registrational design, requiring a broader or redesigned study that the company cannot fund — in either scenario the program stalls and the post-hoc signal remains unvalidated.
Unlock the full thesis for ELTX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.